Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more
Medy-Tox Inc (086900) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.041x
Based on the latest financial reports, Medy-Tox Inc (086900) has a cash flow conversion efficiency ratio of 0.041x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩19.03 Billion) by net assets (₩467.65 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medy-Tox Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medy-Tox Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medy-Tox Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
-0.023x |
|
iHeartMedia Inc Class A
NASDAQ:IHRT
|
0.005x |
|
Scales Corporation Limited
F:S05
|
-0.031x |
|
Qualipoly Chemical Corp
TW:4722
|
0.010x |
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
0.325x |
|
Vinati Organics Limited
NSE:VINATIORGA
|
0.122x |
|
SPAREBKN MORE NK 20
F:K5X
|
N/A |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
0.068x |
Annual Cash Flow Conversion Efficiency for Medy-Tox Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Medy-Tox Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩470.78 Billion | ₩36.89 Billion | 0.078x | +174.98% |
| 2023-12-31 | ₩474.48 Billion | ₩13.52 Billion | 0.028x | -53.44% |
| 2022-12-31 | ₩428.04 Billion | ₩26.20 Billion | 0.061x | +22.47% |
| 2021-12-31 | ₩399.48 Billion | ₩19.97 Billion | 0.050x | -56.80% |
| 2020-12-31 | ₩241.40 Billion | ₩27.93 Billion | 0.116x | -11.05% |
| 2019-12-31 | ₩259.15 Billion | ₩33.70 Billion | 0.130x | -40.35% |
| 2018-12-31 | ₩252.59 Billion | ₩55.07 Billion | 0.218x | -26.10% |
| 2017-12-31 | ₩191.65 Billion | ₩56.55 Billion | 0.295x | -19.46% |
| 2016-12-31 | ₩147.68 Billion | ₩54.10 Billion | 0.366x | +85.86% |
| 2015-12-31 | ₩113.48 Billion | ₩22.37 Billion | 0.197x | -84.74% |
| 2014-12-31 | ₩81.59 Billion | ₩105.38 Billion | 1.292x | +372.27% |
| 2013-12-31 | ₩60.68 Billion | ₩16.60 Billion | 0.273x | -- |